Asterias Biotherapeutics

http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Asterias to report 2018 Q2 results on August 9: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

AST-OPC1 to be investigated for treatment of stroke. Read more here: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Asterias Provides 6-Month Data Readout on AST-OPC1 Phar 1/2 Clinical Trial in Severe Spinal Cord Injury: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Story in San Francisco Chronicle profiling patients seeking out stem cell treatments, including Mary Ambery who is participating in the clinical trial of AST-OPC1.

Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC). Click here to read more: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

First patient dosed in VAC2 study! Read more details here: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Asterias reports Q1 results and recent business progress: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

AST-VAC2 Update: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Asterias releases latest data on AST-OPC1 clinical trial: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Asterias announces it has been issued 46 new patents: http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Enrollment completed for SciStar Study! http://asteriasbiotherapeutics.com/inv_news_releases_text.p

Great feature on Asterias and AST-OPC1.....